Cargando…
RAD51AP1在肿瘤进展和耐药中的研究进展
The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RAD51 associated protein 1 (RAD51AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600754/ https://www.ncbi.nlm.nih.gov/pubmed/37985156 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.34 |
_version_ | 1785126054494470144 |
---|---|
author | LIU, Renwang LI, Mingbiao HU, Zixuan SONG, Zuoqing CHEN, Jun |
author_facet | LIU, Renwang LI, Mingbiao HU, Zixuan SONG, Zuoqing CHEN, Jun |
author_sort | LIU, Renwang |
collection | PubMed |
description | The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RAD51 associated protein 1 (RAD51AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported as an essential protein for maintaining cellular genomic stability. However, recent studies showed that RAD51AP1 was significantly overexpressed in various cancer types and correlated with poor prognosis. These results suggested that RAD51AP1 may play a significant pro-cancer effect in multiple cancers. The underlying mechanism is still unclear. Cancer stemness-maintaining effects of RAD51AP1 might be considered as the most reliable mechanism. Meanwhile, RAD51AP1 also promoted resistance to radiation therapy and chemotherapy in many cancers. Thus, researches focused on RAD51AP1, and its regulatory molecules may provide new targets for overcoming cancer progression and treatment resistance. Here, we reviewed the latest research on RAD51AP1 in cancers and summarized its differential expression and prognostic implications. In this review, we also outlined the potential mechanisms of its pro-cancer and drug resistance-promoting effects to provide several potential directions for further research. |
format | Online Article Text |
id | pubmed-10600754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial board of Chinese Journal of Lung Cancer |
record_format | MEDLINE/PubMed |
spelling | pubmed-106007542023-10-27 RAD51AP1在肿瘤进展和耐药中的研究进展 LIU, Renwang LI, Mingbiao HU, Zixuan SONG, Zuoqing CHEN, Jun Zhongguo Fei Ai Za Zhi Review The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RAD51 associated protein 1 (RAD51AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported as an essential protein for maintaining cellular genomic stability. However, recent studies showed that RAD51AP1 was significantly overexpressed in various cancer types and correlated with poor prognosis. These results suggested that RAD51AP1 may play a significant pro-cancer effect in multiple cancers. The underlying mechanism is still unclear. Cancer stemness-maintaining effects of RAD51AP1 might be considered as the most reliable mechanism. Meanwhile, RAD51AP1 also promoted resistance to radiation therapy and chemotherapy in many cancers. Thus, researches focused on RAD51AP1, and its regulatory molecules may provide new targets for overcoming cancer progression and treatment resistance. Here, we reviewed the latest research on RAD51AP1 in cancers and summarized its differential expression and prognostic implications. In this review, we also outlined the potential mechanisms of its pro-cancer and drug resistance-promoting effects to provide several potential directions for further research. Editorial board of Chinese Journal of Lung Cancer 2023-09-20 /pmc/articles/PMC10600754/ /pubmed/37985156 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.34 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | Review LIU, Renwang LI, Mingbiao HU, Zixuan SONG, Zuoqing CHEN, Jun RAD51AP1在肿瘤进展和耐药中的研究进展 |
title | RAD51AP1在肿瘤进展和耐药中的研究进展 |
title_full | RAD51AP1在肿瘤进展和耐药中的研究进展 |
title_fullStr | RAD51AP1在肿瘤进展和耐药中的研究进展 |
title_full_unstemmed | RAD51AP1在肿瘤进展和耐药中的研究进展 |
title_short | RAD51AP1在肿瘤进展和耐药中的研究进展 |
title_sort | rad51ap1在肿瘤进展和耐药中的研究进展 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600754/ https://www.ncbi.nlm.nih.gov/pubmed/37985156 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.34 |
work_keys_str_mv | AT liurenwang rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn AT limingbiao rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn AT huzixuan rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn AT songzuoqing rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn AT chenjun rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn |